本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

康乃德生物医药

2.12
+0.440026.19%
成交量:104.36万
成交额:204.89万
市值:1.19亿
市盈率:-2.61
高:2.17
开:1.61
低:1.59
收:1.68
52周最高:2.86
52周最低:0.5100
股本:5,590.35万
流通股本:1,434.41万
量比:7.76
换手率:7.28%
股息:- -
股息率:- -
每股收益(TTM):-0.8133
每股收益(LYR):-0.2830
净资产收益率:-66.80%
总资产收益率:-38.67%
市净率:2.14
市盈率(LYR):-7.49

数据加载中...

2024/07/01

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/04/16

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/27

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/27

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/13

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/02/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/12/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/12/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/14

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/12/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/04

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/10/05

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/07/24

SEC问询函

Form CORRESP - Correspondence